Tandem Diabetes Care (TNDM) Revenue (2013 - 2026)

Tandem Diabetes Care's Revenue history runs 14 years deep, the most recent figure standing at $247.2 million for Q1 2026.

• Quarterly Revenue rose 5.46% year-over-year to $247.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 4.54% YoY) and the FY2025 annual result came in at $1.0 billion, up 7.93% from the prior year.
• Revenue was $247.2 million for Q1 2026 at Tandem Diabetes Care, down from $290.4 million in the prior quarter.
• Across five years, Revenue topped out at $290.4 million in Q4 2025 and bottomed at $169.4 million in Q1 2023.
• A 5-year average of $220.7 million and a median of $220.5 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue decreased 10.75% — and 2024, when it soared 43.62%.
• Tandem Diabetes Care's Revenue stood at $220.5 million in 2022, then declined by 10.75% to $196.8 million in 2023, then soared by 43.62% to $282.6 million in 2024, then rose by 2.74% to $290.4 million in 2025, then slipped by 14.86% to $247.2 million in 2026.
• Business Quant data shows TNDM's Revenue at $247.2 million in Q1 2026, $290.4 million in Q4 2025, and $249.3 million in Q3 2025.